Please login to the form below

Not currently logged in
Email:
Password:

anaemia

This page shows the latest anaemia news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

Rigel is also developing it for additional indications, including autoimmune haemolytic anaemia and IgA nephropathy.

Latest news

More from news
Approximately 9 fully matching, plus 143 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    It is not known why in December 2015 the territorial rights granted to Mitsubishi for vadadustat for treatment of anaemia, were limited to Japan, SE Asia and India. ... 1, 050. Akebia (US). Otsuka (JP). Licence expansion selected countries. Vadadustat in

  • Deal Watch December 2016 Deal Watch December 2016

    1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease.

  • Focusing on value Focusing on value

    in Brazil, involving the iron deficiency related anaemia treatment Anemidox/Confer and liver protector Hepabionta. “

  • Deal Watch February 2016 Deal Watch February 2016

    licence. 105. †† Genexine/ Shanghai Chemo WanBang Biopharma. GX-E2 (EPO-hyFc), a novel Fc-engineered (hyFc) long acting EPO, for anaemia due to chronic kidney disease and chemotherapy. ... investment. 42.5. ††† Rockwell Medical Technologies/

  • Deal Watch December 2015 Deal Watch December 2015

    397. Akebia (US). Mitsubishi. Collaboration, licence. Vadadustat for treatment of anaemia in chronic kidney disease.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Joined-up thinking on anaemia

    Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’ s quality of life, but it’ s often under-treated. ... Pharmacosmos is committed to improving the lives of patients with iron deficiency anaemia

  • Living with Crohn's disease: a patient perspective

    It’ s also a very individual condition. The most common symptoms are not only diarrhoea, but also tiredness and fatigue, abdominal pain, mouth ulcers, anaemia, loss of appetite, and weight loss.

  • Patient Power: Too Much of a Good Thing?

    It commonly causes abdominal pain, diarrhoea, weight loss and vomiting but because it affects the immune system it can cause other problems such as anaemia, arthritis, lack of concentration, tiredness and

  • PMHub content search

    Search for a healthcare communications agency

  • PMHub content search

    Search for a healthcare communications agency

More from PMHub
Approximately 1 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics